Moreover, a study from Cai et al. (2018) reported that PER3 expression is lower in paclitaxel-resistant PCa cells, and PER3 OE in PCa resistant cells inhibits cell proliferation, arrests the cell cycle and increases apoptosis, which induce therapeutic sensitivity to paclitaxel by downregulating NOTCH1 signaling pathway, further supporting our suggestion that PER3 is of clinical and therapeutic value. Here, PER3 is linked to posterior cortical atrophy.